Ameritas Investment Partners’s Myriad Genetics MYGN Stock Holding History

Ameritas Investment Partners’s Portfolio MYGN Stock Details MYGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$43.9K	Hold	7,687	–	–	﹤0.01%	2323
2026 Q1	$34.6K	Hold	7,687	–	–	﹤0.01%	2309
2025 Q4	$47.3K	Sell	7,687 -1,060	-12%	-$7.69K	﹤0.01%	2166
2025 Q3	$63.2K	Hold	8,747	–	–	﹤0.01%	1968
2025 Q2	$46.4K	Hold	8,747	–	–	﹤0.01%	2232
2025 Q1	$77.6K	Hold	8,747	–	–	﹤0.01%	1867
2024 Q4	$120K	Hold	8,747	–	–	﹤0.01%	1650
2024 Q3	$240K	Hold	8,747	–	–	0.01%	1196
2024 Q2	$214K	Hold	8,747	–	–	0.01%	1219
2024 Q1	$186K	Buy	8,747 +720	+9%	+$15.5K	0.01%	1339
2023 Q4	$154K	Hold	8,027	–	–	0.01%	1452
2023 Q3	$129K	Buy	8,027 +1,356	+20%	+$25.8K	0.01%	1478
2023 Q2	$155K	Buy	6,671 +605	+10%	+$13.2K	0.01%	1303
2023 Q1	$141K	Hold	6,066	–	–	0.01%	1301
2022 Q4	$130K	Hold	6,066	–	–	0.01%	1404
2022 Q3	$115K	Hold	6,066	–	–	0.01%	1398
2022 Q2	$110K	Hold	6,066	–	–	﹤0.01%	1437
2022 Q1	$153K	Hold	6,066	–	–	0.01%	1359
2021 Q4	$167K	Hold	6,066	–	–	0.01%	1339
2021 Q3	$196K	Buy	6,066 +275	+5%	+$9.13K	0.01%	1213
2021 Q2	$177K	Hold	5,791	–	–	0.01%	1338
2021 Q1	$176K	Sell	5,791 -358	-6%	-$10.2K	0.01%	1301
2020 Q4	$122K	Hold	6,149	–	–	0.01%	1452
2020 Q3	$80K	Hold	6,149	–	–	﹤0.01%	1570
2020 Q2	$70K	Hold	6,149	–	–	﹤0.01%	1627
2020 Q1	$88K	Hold	6,149	–	–	0.01%	1350
2019 Q4	$167K	Buy	6,149 +334	+6%	+$9.19K	0.01%	1209
2019 Q3	$166K	Hold	5,815	–	–	0.01%	1160
2019 Q2	$162K	Hold	5,815	–	–	0.01%	1182
2019 Q1	$193K	Buy	5,815 +290	+5%	+$8.83K	0.01%	1068
2018 Q4	$161K	Hold	5,525	–	–	0.01%	1078
2018 Q3	$254K	Hold	5,525	–	–	0.01%	955
2018 Q2	$206K	Hold	5,525	–	–	0.01%	1054
2018 Q1	$163K	Hold	5,525	–	–	0.01%	1183
2017 Q4	$190K	Hold	5,525	–	–	0.01%	1112
2017 Q3	$168K	Sell	5,525 -305	-5%	-$8.7K	0.01%	1152
2017 Q2	$151K	Hold	5,830	–	–	0.01%	1207
2017 Q1	$112K	Buy	+5,830	New	+$103K	0.01%	1354
2016 Q2	–	Sell	-30,660	Closed	-$1.15M	–	1188
2016 Q1	$1.15M	Hold	30,660	–	–	0.08%	258
2015 Q4	$1.32M	Buy	30,660 +25,300	+472%	+$1.07M	0.09%	235
2015 Q3	$201K	Buy	+5,360	New	+$190K	0.01%	928
2013 Q4	–	Sell	-21,100	Closed	-$495K	–	1069
2013 Q3	$495K	Buy	+21,100	New	+$599K	0.05%	521

Other funds holding MYGN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Ameritas Investment Partners's MYGN Position: Q2 2026 in Review

Ameritas Investment Partners held its Myriad Genetics (MYGN) position steady in Q2 2026 at 7,687 shares worth $43.9K. The position accounts for ﹤0.01% of the portfolio, ranked #2323.

Ameritas Investment Partners first reported a position in MYGN in Q3 2013 and has held it in 42 quarters since. The position peaked at $1.32M in Q4 2015. 196 funds tracked by Wall St. Rank hold MYGN as of Q2 2026.

Ameritas Investment Partners held 7,687 shares of Myriad Genetics worth $43.9K as of Q2 2026.
Ameritas Investment Partners left its Myriad Genetics share count unchanged in Q2 2026.
Myriad Genetics made up ﹤0.01% of Ameritas Investment Partners's portfolio in Q2 2026, its #2323 holding.
Ameritas Investment Partners first reported a position in Myriad Genetics in Q3 2013 and has held it in 42 quarters since.
Ameritas Investment Partners's Myriad Genetics position peaked at $1.32M in Q4 2015.
196 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2026.

Based on Ameritas Investment Partners's 13F filing for Q2 2026, filed 13 Aug 2026.